3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
21
NIH
4
NETWORK
3
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Arthritis, Rheumatoid
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Graft vs Host Disease
6
Leukemia
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Lymphoma
3
Psoriasis
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Accelerated Phase
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Stomatitis
1
Recurrence
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neutropenia
1
Mycosis Fungoides
1
Multiple Myeloma
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Interventions
Pemetrexed
3
mifamurtide
2
lenvatinib
2
dostarlimab
2
belinostat
2
Ifosfamide
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gemcitabine
2
Etoposide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
vactosertib
1
surufatinib
1
sintilimab
1
robatumumab
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
omburtamab I-131
1
niraparib
1
isophosphamide mustard
1
fludarabine
1
endostar protein
1
dinutuximab
1
copanlisib
1
cc-486
1
cabozantinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Osteosarcoma
×
Methotrexate
×
Clear all
NCT02383901
2016-09-05
FORTO
Isofol Medical AB
Completed
116 enrolled